Get the Stockscreener App
3.07
1.29%
-0.04
Savara Inc stock is traded at $3.07, with a volume of 689.83K.
It is down -1.29% in the last 24 hours and up +4.78% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$3.11
Open:
$3.11
24h Volume:
689.83K
Relative Volume:
0.73
Market Cap:
$530.62M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-9.303
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
+7.34%
1M Performance:
+4.78%
6M Performance:
+3.02%
1Y Performance:
-34.96%
1-Day Range:
$3.07
$3.20
1-Week Range:
$2.77
$3.20
52-Week Range:
$2.31
$5.11
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
3.07 | 493.73M | 0 | -54.70M | -51.36M | -0.33 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara Inc (NASDAQ:SVRA) Shares Purchased by Dimensional Fund Advisors LP - Defense World
HC Wainwright Has Positive Forecast for Savara Q2 Earnings - Defense World
Savara (SVRA) Price Target Lowered as Molbreevi Priority Review Anticipated | SVRA Stock News - GuruFocus
Savara (SVRA) Prepares for U.S. Launch Following BLA Submission - GuruFocus
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update | SVRA Stock News - GuruFocus
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update - Business Wire
Autoimmune Pulmonary Alveolar Proteinosis Market to Expand Significantly by 2032, States DelveInsight Report | Savara Inc. - Barchart.com
Hsbc Holdings PLC Invests $48,000 in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference - Stock Titan
Savara Inc.'s (NASDAQ:SVRA) recent 16% pullback adds to one-year year losses, institutional owners may take drastic measures - simplywall.st
Wells Fargo & Company MN Has $182,000 Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Sold by MetLife Investment Management LLC - Defense World
Analysts Set Savara Inc (NASDAQ:SVRA) Target Price at $8.83 - Defense World
Barclays PLC Grows Stake in Savara Inc (NASDAQ:SVRA) - Defense World
Metric Deep Dive: Understanding Savara Inc (SVRA) Through its Ratios - DWinneX
Raymond James Financial Inc. Buys Shares of 259,798 Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
A stock that deserves closer examination: Savara Inc (SVRA) - uspostnews.com
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference - Business Wire
Legal & General Group Plc Sells 12,613 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara, Inc. to Host Earnings Call - ACCESS Newswire
Savara Inc (NASDAQ:SVRA) Shares Purchased by Geode Capital Management LLC - Defense World
JMP maintains $10 target on Savara stock post-BLA submission By Investing.com - Investing.com Nigeria
Examining Savara Inc (SVRA) more closely is necessary - uspostnews.com
JMP maintains $10 target on Savara stock post-BLA submission - Investing.com
Savara: Make-It-Or-Break-It Molbreevi BLA Filing (NASDAQ:SVRA) - Seeking Alpha
Savara Inc. Announces Equity Awards for New Employees - MSN
JPMorgan Chase & Co. Grows Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Purchased by Vanguard Group Inc. - Defense World
Corebridge Financial Inc. Sells 4,330 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
KLP Kapitalforvaltning AS Purchases Shares of 13,200 Savara Inc (NASDAQ:SVRA) - Defense World
Savara Announces New Employment Inducement Grant | SVRA Stock Ne - GuruFocus
Savara Announces New Employment Inducement Grant - Enidnews.com
Savara's Bold Move: 190K Share Grant Signals Aggressive Growth Strategy - Stock Titan
Savara Inc (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Savara to present aPAP treatment study at medical congresses By Investing.com - Investing.com Canada
Savara to present aPAP treatment study at medical congresses - Investing.com
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - MarketScreener
Breakthrough Phase 3 Results: New Treatment Could Transform Rare Lung Disease Management - Stock Titan
259,798 Shares in Savara Inc (NASDAQ:SVRA) Bought by Raymond James Financial Inc. - Defense World
Raymond James Financial Inc. Invests $798,000 in Savara Inc (NASDAQ:SVRA) - The AM Reporter
Savara Completes BLA Submission for MOLBREEVI to Treat aPAP - MSN
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt? - simplywall.st
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Savara Inc Stock (SVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):